Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117464) titled 'An observational clinical study on the maintenance treatment of advanced NSCLC patients with recombinant human endostatin combined with immunotherapy' on Jan. 23.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: HenanCancerHospital
Condition:
Unresectable locally advanced/advanced non-small cell lung cancer
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-23
Target Sample Size: Experimental Group:33;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=307572
Disclaimer: Curated by HT Syndication....